analyse_media

Reading File

This is a set of 16 exam questions covering enzyme biochemistry (mechanism, kinetics, inhibition, regulation, isoenzymes, clinical enzymology). That's too much to cover in full detail in one response, so here's the topic map and a quick overview - then tell me which one you want a full detailed answer for.

Topic breakdown (as numbered in your paper):

Q2 - Mechanism of action of enzymes (5 marks)
Q3 - Factors affecting enzyme activity (10 marks)
Q4 - Types of enzyme inhibition with examples (5 marks)
Q5 - Allosteric enzymes (3 marks)
Q6 - Regulation of enzyme activity (5 marks)
Q7 - Isoenzymes + 2 clinically important examples (5 marks)
Q8 - Allopurinol/gout - type of inhibition & mechanism (5 marks)
Q9 - Active site: definition & characteristics (3 marks)
Q10 - Theories of enzyme-substrate binding (5 marks)
Q11 - Km definition & significance with examples (3 marks)
Q12 - Types of enzyme specificity with examples (5 marks)
Q13 - Therapeutic applications of enzymes (3/5 marks)
Q14 - Enzyme profile in myocardial infarction (5 marks)
Q15 - Coenzymes & role in metabolism, 2 examples (3 marks)
Q16 - Proenzymes (zymogens), 2 examples (3 marks)
Q17 - 5 diagnostic enzymes with normal serum levels (5 marks)

Quick overview: These questions form a standard enzymology unit typical of first/second-year MBBS or allied health biochemistry papers. They flow logically: enzyme structure/action (active site, lock-and-key vs induced fit) → kinetics (Km, Vmax) → factors affecting activity (pH, temperature, substrate/enzyme concentration) → regulation (allosteric control, zymogen activation, covalent modification) → inhibition (competitive - e.g. allopurinol on xanthine oxidase, non-competitive, uncompetitive) → clinical enzymology (isoenzymes like CK-MB/LDH, diagnostic markers in MI - CK-MB, troponin, LDH, AST; and enzymes used therapeutically, e.g. streptokinase).

Given there are 16 separate questions, I'll go deep on whichever ones you need most (e.g. for an upcoming exam or assignment).

Asking for Preferences

Which question(s) would you like a full detailed answer for first?

Topic breakdown (as numbered in your paper):

Q2 - Mechanism of action of enzymes (5 marks)
Q3 - Factors affecting enzyme activity (10 marks)
Q4 - Types of enzyme inhibition with examples (5 marks)
Q5 - Allosteric enzymes (3 marks)
Q6 - Regulation of enzyme activity (5 marks)
Q7 - Isoenzymes + 2 clinically important examples (5 marks)
Q8 - Allopurinol/gout - type of inhibition & mechanism (5 marks)
Q9 - Active site: definition & characteristics (3 marks)
Q10 - Theories of enzyme-substrate binding (5 marks)
Q11 - Km definition & significance with examples (3 marks)
Q12 - Types of enzyme specificity with examples (5 marks)
Q13 - Therapeutic applications of enzymes (3/5 marks)
Q14 - Enzyme profile in myocardial infarction (5 marks)
Q15 - Coenzymes & role in metabolism, 2 examples (3 marks)
Q16 - Proenzymes (zymogens), 2 examples (3 marks)
Q17 - 5 diagnostic enzymes with normal serum levels (5 marks)

Given there are 16 separate questions, I'll go deep on whichever ones you need most (e.g. for an upcoming exam or assignment).

Fine me answers to ask questions

Finding Sources

Enzymology - Answers to All Questions

Q2. Mechanism of action of enzymes [5 marks]

Enzymes are biological catalysts that lower the activation energy of a reaction without altering the equilibrium or being consumed.

Active site binding: The enzyme has a specific three-dimensional cleft (active site) that binds the substrate to form an enzyme-substrate (ES) complex.
Lowering activation energy: The enzyme stabilizes the transition state of the reaction, so less energy is needed for the reaction to proceed, increasing the reaction rate (often 10^6-10^12 fold).
Mechanisms used at the active site:
- Proximity and orientation effect - substrates are brought close together in the correct orientation.
- Strain/distortion (induced fit) - enzyme binding strains the substrate bonds toward the transition state.
- General acid-base catalysis - amino acid side chains donate/accept protons.
- Covalent catalysis - a transient covalent bond forms between enzyme and substrate.
- Metal ion catalysis - cofactors like Zn2+, Mg2+ stabilize charges or participate in redox.
Product is released and the enzyme returns to its original state, ready for another catalytic cycle (Biochemistry, 8th ed - Lippincott Illustrated Reviews, "Mechanism of Enzyme Action").

Q3. Factors affecting enzyme activity [10 marks]

Factor	Effect
Temperature	Activity rises with temperature up to an optimum (~37°C in humans); beyond this, denaturation occurs and activity falls sharply
pH	Each enzyme has an optimum pH (e.g. pepsin ~1.5-2, trypsin ~8); extremes alter ionization of active-site residues and denature the protein
Substrate concentration [S]	Velocity increases with [S] until Vmax is reached (saturation of active sites), following Michaelis-Menten kinetics
Enzyme concentration	Velocity is directly proportional to enzyme concentration when substrate is in excess
Presence of activators/cofactors	Coenzymes and metal ions (e.g. Mg2+, Zn2+) are often mandatory for activity
Presence of inhibitors	Competitive, non-competitive, uncompetitive inhibitors reduce activity
Product concentration	Accumulation of product can cause feedback/product inhibition
Allosteric effectors	Positive or negative modulators bind at sites other than the active site and change conformation/activity
Covalent modification	Phosphorylation/dephosphorylation, proteolytic cleavage of zymogens
Ionic strength/pressure	High salt concentration or pressure can also alter enzyme conformation and activity

Q4. Types of enzyme inhibition with examples [5 marks]

1. Reversible inhibition (non-covalent, dissociable):

Competitive: Inhibitor resembles substrate structurally and competes for the active site. Increases apparent Km, Vmax unchanged. Effect reversed by increasing [S]. Example: Allopurinol inhibiting xanthine oxidase; malonate inhibiting succinate dehydrogenase; methotrexate inhibiting dihydrofolate reductase.
Non-competitive: Inhibitor binds at a site other than the active site (on E or ES complex), does not compete with substrate. Km unchanged, Vmax decreased. Example: Heavy metals (Pb2+, Hg2+) on sulfhydryl-dependent enzymes.
Uncompetitive: Inhibitor binds only to the ES complex, not free enzyme. Both Km and Vmax decrease. Example: Lithium on inositol monophosphatase.

2. Irreversible inhibition: Inhibitor forms a stable covalent bond with the enzyme (often at or near active site), permanently inactivating it. Example: Organophosphates (e.g. DIPF, nerve agents, some insecticides) on acetylcholinesterase; aspirin irreversibly acetylating cyclooxygenase (COX).

Q5. Allosteric enzymes [3 marks]

Allosteric enzymes are regulatory enzymes, usually with multiple subunits (oligomeric), that possess a distinct allosteric site separate from the catalytic active site. Binding of an effector molecule (activator or inhibitor) at this site changes the enzyme's conformation, altering affinity for the substrate at the active site.

Do not follow simple Michaelis-Menten kinetics; velocity vs [S] plot is sigmoidal (not hyperbolic) due to cooperativity between subunits.
Often function at key regulatory/rate-limiting steps of metabolic pathways.
Examples: Phosphofructokinase-1 (glycolysis, inhibited by ATP/citrate, activated by AMP/fructose-2,6-bisphosphate), aspartate transcarbamoylase, glycogen phosphorylase.

Q6. Regulation of enzyme activity [5 marks]

Cells regulate enzyme activity by several complementary mechanisms:

Allosteric regulation: Binding of activators/inhibitors at a site distinct from the active site (e.g. feedback inhibition of the first enzyme of a pathway by the end product).
Covalent modification: Reversible phosphorylation/dephosphorylation (e.g. glycogen phosphorylase activated by phosphorylation via phosphorylase kinase), or other modifications like adenylylation, methylation.
Proteolytic activation (zymogen activation): Irreversible cleavage converts an inactive precursor to an active enzyme (e.g. trypsinogen -> trypsin).
Control of enzyme amount:
- Induction/repression of gene transcription (changes rate of synthesis)
- Regulation of enzyme degradation (protein turnover, ubiquitin-proteasome pathway)
Isoenzymes: Different tissue-specific forms allow tissue-appropriate regulation.
Compartmentalization: Localizing enzymes to specific organelles keeps competing pathways separate.
Availability of substrate/cofactors and second messengers (e.g. Ca2+-calmodulin, cAMP).

Q7. Isoenzymes - definition & clinically important examples [5 marks]

Isoenzymes (isozymes) are physically distinct forms of the same enzyme (catalyzing the same reaction) that differ in their amino acid sequence, physical properties (electrophoretic mobility, kinetics), and tissue distribution, but often arise from different combinations of subunits encoded by different genes.

Two clinically important isoenzymes:

Creatine kinase (CK): A dimer of M and B subunits giving three isoenzymes:
- CK-MM (skeletal muscle)
- CK-MB (cardiac muscle) - elevated specifically in myocardial infarction, rises within 4-6 hours, peaks ~24 hours
- CK-BB (brain)
Lactate dehydrogenase (LDH): A tetramer of H (heart) and M (muscle) subunits giving 5 isoenzymes (LDH1-LDH5):
- LDH1 (H4) - predominant in heart and RBCs, rises in MI
- LDH5 (M4) - predominant in liver and skeletal muscle, rises in liver disease
- In MI, the LDH1/LDH2 ratio "flips" (LDH1 > LDH2), useful historically for late-presenting MI (Quick Compendium of Clinical Pathology, "Lactate dehydrogenase").

(Alkaline phosphatase isoenzymes - bone vs liver - are another commonly cited example, useful in differentiating bone from hepatobiliary disease.)

Q8. Allopurinol in gout - type of inhibition & mechanism [5 marks]

Allopurinol is a competitive inhibitor of xanthine oxidase (structural analog of hypoxanthine).

Mechanism:

Xanthine oxidase normally converts hypoxanthine -> xanthine -> uric acid.
Allopurinol competes with hypoxanthine/xanthine for the active site of xanthine oxidase.
Allopurinol itself is oxidized by xanthine oxidase to oxypurinol (alloxanthine), which binds very tightly to the reduced form of the enzyme and acts almost like an irreversible/suicide-type inhibitor in vivo (mechanism-based inhibition), giving a prolonged inhibitory effect.
Net effect: decreased conversion of purines to uric acid, lowering serum and urinary uric acid levels, and diverting purine metabolism toward more soluble precursors (hypoxanthine, xanthine) that are more easily excreted.
This reduces urate crystal deposition in joints (gout) and tissues.
Note (from Katzung's Pharmacology): allopurinol also competitively inhibits the metabolism of other purine-analog drugs like mercaptopurine and azathioprine by the same enzyme, so their doses must be reduced when co-administered - Katzung's Basic and Clinical Pharmacology, Table 4-5.

Q9. Active site of an enzyme - definition & characteristics [3 marks]

Definition: The active site is a small, specific three-dimensional pocket or cleft on the enzyme surface, formed by amino acid residues (often from different parts of the polypeptide chain folded together), where the substrate binds and the catalytic reaction occurs.

Characteristics:

Occupies a relatively small part of the total enzyme volume.
Three-dimensional cleft/pocket formed by residues from different regions of the primary sequence brought together by tertiary folding.
Substrate binds through relatively weak, non-covalent forces (H-bonds, ionic, hydrophobic, van der Waals).
Specific in shape and chemical properties - only substrates with complementary structure can bind (specificity).
Contains catalytic residues in addition to substrate-binding residues.
Not rigid - can change shape on substrate binding (induced fit) to achieve optimal catalysis.
Often located in a cleft that excludes bulk water, creating a favorable microenvironment for catalysis.

Q10. Theories of enzyme-substrate binding [5 marks]

1. Lock-and-Key model (Emil Fischer, 1894): The active site has a fixed, rigid shape exactly complementary to the substrate, like a key fitting into a lock. Explains specificity but not why some structurally similar analogs also bind (and inhibit).

2. Induced-Fit model (Daniel Koshland, 1958): The active site is flexible, not rigid. Substrate binding induces a conformational change in the enzyme so the active site molds itself around the substrate, bringing catalytic groups into proper alignment. This model better explains:

Catalysis of the transition state
Why some substrate analogs bind but are not catalyzed
Cooperativity in allosteric enzymes

Both models help explain enzyme specificity, but the induced-fit model is more widely accepted today as it accounts for the dynamic, flexible nature of enzymes observed by X-ray crystallography and other structural studies.

Q11. Km of an enzyme - definition & significance [3 marks]

Definition: Km (Michaelis constant) is the substrate concentration at which the reaction velocity is half of Vmax (maximum velocity). It is derived from the Michaelis-Menten equation: v = Vmax[S] / (Km + [S]).

Significance:

Measure of affinity: Km is inversely related to the enzyme's affinity for its substrate - a low Km indicates high affinity (enzyme reaches half-maximal velocity at low substrate concentration), and a high Km indicates low affinity.
Helps compare different enzymes acting on the same substrate, or the same enzyme with different substrates.
Useful in distinguishing isoenzymes (e.g. hexokinase has a low Km for glucose vs glucokinase's high Km, allowing tissue-specific regulation of glucose metabolism - liver glucokinase only becomes active at high glucose concentrations).
Helps determine the physiological substrate concentration range in which an enzyme normally operates (usually enzymes function near their Km in vivo, allowing sensitive regulation of flux).
Important in understanding drug/inhibitor kinetics - e.g., competitive inhibitors increase the apparent Km.

Example: Hexokinase (Km ~0.1 mM, high affinity, found in most tissues) vs. Glucokinase (Km ~10 mM, low affinity, found in liver/pancreatic beta cells, acts as a glucose sensor).

Q12. Types of enzyme specificity with examples [5 marks]

Absolute substrate specificity: Enzyme acts on only one substrate. Example: Glucokinase acts only on glucose; urease acts only on urea.
Group/relative specificity: Enzyme acts on structurally related molecules sharing a common functional group. Example: Hexokinase phosphorylates glucose, fructose, mannose; alcohol dehydrogenase acts on various alcohols; pepsin/trypsin act on peptide bonds adjacent to certain amino acids.
Bond specificity: Enzyme acts on a particular type of chemical bond, regardless of the rest of the molecular structure. Example: Lipases hydrolyze ester bonds in triglycerides; phosphatases hydrolyze phosphate ester bonds.
Stereospecificity (optical specificity): Enzyme acts on only one stereoisomer (e.g., L- or D-form) of a substrate. Example: L-amino acid oxidase acts only on L-amino acids; enzymes of glycolysis act only on D-glucose.
Geometric specificity (less strict form): Enzyme is somewhat less discriminating about the fine structure of the substrate as long as the general geometry is compatible.
Co-factor specificity: Some enzymes require a specific coenzyme/cofactor to act on the substrate.

Q13. Therapeutic applications of enzymes [3/5 marks]

Category	Enzyme	Use
Thrombolytic	Streptokinase, Urokinase, tissue plasminogen activator (t-PA/Alteplase)	Dissolve clots in acute MI, stroke, pulmonary embolism
Digestive aid	Pancreatic enzymes (lipase, amylase, protease/pancreatin)	Replacement therapy in chronic pancreatitis, cystic fibrosis
Anti-neoplastic	L-Asparaginase	Depletes asparagine, used in acute lymphoblastic leukemia (ALL)
Debridement	Collagenase, papain-urea, streptodornase	Wound/burn debridement, removing necrotic tissue
Enzyme replacement	Alglucosidase alfa, imiglucerase	Pompe disease, Gaucher's disease (lysosomal storage disorders)
Diagnostic reagents	Glucose oxidase, urease, cholesterol esterase	Used in clinical lab kits for estimating glucose, urea, cholesterol
Anti-gout	Rasburicase (recombinant urate oxidase)	Rapid reduction of uric acid in tumor lysis syndrome
Digestive/anti-inflammatory	Trypsin, chymotrypsin	Anti-inflammatory, wound healing
Hemophilia/genetic disorders	Recombinant Factor VIII/IX	Enzyme/factor replacement

Q14. Enzyme profile in myocardial infarction [5 marks]

After myocardial cell necrosis, intracellular enzymes leak into the bloodstream in a characteristic time-sequence:

Enzyme/Marker	Onset of rise	Peak	Return to normal	Notes
CK-MB	4-6 hours	18-24 hours	2-3 days	Cardiac-specific isoenzyme, classic early marker
Troponin I/T	3-6 hours	12-24 hours	7-10 days (T) / 5-7 days (I)	Most sensitive and specific marker used today, remains elevated longest
AST (SGOT)	6-8 hours	24-36 hours	3-4 days	Less specific (also in liver, skeletal muscle)
LDH (LDH1)	24-48 hours	3-6 days	8-14 days	Late and prolonged rise; LDH1/LDH2 ratio flip was used historically
Myoglobin	1-4 hours	6-12 hours	24 hours	Earliest to rise but not cardiac-specific

Clinical significance: Serial measurement of these markers (especially troponin and CK-MB) helps confirm diagnosis of MI, estimate infarct size, and detect reinfarction (a second CK-MB rise after it has normalized suggests re-infarction) - Ganong's Review of Medical Physiology, "Coronary Artery Disease."

Q15. Coenzymes - definition, role in metabolism, examples [3 marks]

Definition: Coenzymes are small, non-protein organic molecules (often derived from vitamins) that bind to an enzyme (apoenzyme) and are essential for its catalytic activity. The complete active enzyme (apoenzyme + coenzyme) is called a holoenzyme.

Role in metabolism: Coenzymes typically act as carriers, transiently accepting and transferring specific chemical groups, electrons, or atoms during catalysis - e.g., transferring hydride ions/electrons in oxidation-reduction reactions, or transferring functional groups like acyl, amino, or one-carbon groups between substrates.

Examples:

NAD+/NADH (derived from niacin/vitamin B3): Acts as an electron/hydride carrier in oxidation-reduction reactions, e.g., in glycolysis, citric acid cycle, and oxidative phosphorylation.
Coenzyme A (CoA) (derived from pantothenic acid): Carries and activates acyl groups, e.g., forming acetyl-CoA in fatty acid oxidation and the citric acid cycle.

(Other examples: TPP/thiamine in pyruvate dehydrogenase, FAD/FMN in succinate dehydrogenase, pyridoxal phosphate/vitamin B6 in transamination, biotin in carboxylation reactions.)

Q16. Proenzymes (zymogens) - definition & examples [3 marks]

Definition: Proenzymes (zymogens) are inactive precursor forms of enzymes that are activated by limited, irreversible proteolytic cleavage, which removes a peptide segment and allows the enzyme to fold into its catalytically active conformation. This mechanism protects the secreting cell/tissue from premature/inappropriate enzymatic digestion.

Examples:

Trypsinogen -> Trypsin: Secreted by pancreatic acinar cells, activated in the duodenum by enteropeptidase (enterokinase), which cleaves off a hexapeptide. Trypsin then autoactivates more trypsinogen and other pancreatic zymogens (chymotrypsinogen, procarboxypeptidase, proelastase, prophospholipase A2) - Sleisenger and Fordtran's Gastrointestinal and Liver Disease.
Pepsinogen -> Pepsin: Secreted by gastric chief cells, activated by the acidic gastric environment (HCl) and autocatalytically by pepsin itself.

(Other examples: Prothrombin -> Thrombin in the coagulation cascade; Plasminogen -> Plasmin in fibrinolysis; Procarboxypeptidase -> Carboxypeptidase.)

Q17. Five diagnostic enzymes with normal serum levels [5 marks]

Enzyme	Approx. Normal Serum Level	Clinical Significance
Alanine aminotransferase (ALT/SGPT)	~7-40 U/L	Liver damage (more liver-specific than AST)
Aspartate aminotransferase (AST/SGOT)	~8-40 U/L	Liver disease, myocardial infarction, muscle injury
Creatine kinase (CK), especially CK-MB	Total CK ~30-170 U/L (CK-MB <5% of total, or <25 U/L)	Myocardial infarction, muscle disorders
Alkaline phosphatase (ALP)	~40-129 U/L (adults)	Bone disease, cholestatic/obstructive liver disease
Amylase	~30-110 U/L	Acute pancreatitis, salivary gland disorders
Lipase	~0-160 U/L	More specific than amylase for acute pancreatitis
Lactate dehydrogenase (LDH)	~100-190 U/L	Hemolysis, MI, tissue necrosis, tumor lysis
Gamma-glutamyl transferase (GGT)	~9-48 U/L	Hepatobiliary disease, chronic alcohol use

(Reference ranges vary somewhat by lab/method - pick any 5 of the above for a 5-mark answer; the classic teaching set is usually AST, ALT, ALP, CK, and Amylase/LDH.)

Sources: Lippincott Illustrated Reviews Biochemistry (8th ed.), Basic Medical Biochemistry - A Clinical Approach (6e), Harper's Illustrated Biochemistry (32nd ed.), Ganong's Review of Medical Physiology (26th ed.), Katzung's Basic and Clinical Pharmacology (16th ed.), Quick Compendium of Clinical Pathology (5th ed.), Sleisenger and Fordtran's Gastrointestinal and Liver Disease.

Let me know if you'd like any single question expanded further (e.g. a diagram of Lineweaver-Burk plots for the inhibition types, or a table comparing all isoenzymes) or if you want this compiled into a printable notes document.

This is a shared conversation. Sign in to Orris to start your own chat.